The downside correction in NovoCure (NVCR) looks like it has run its course. NVCR is looking ready to resume its uptrend.
More from Investing
Qualcomm's shares moved lower after it forecast strong growth for a chip business that will benefit from 5G adoption, but offered a more measured growth outlook for its patent-licensing business.
Apple turns red, retail slumps and small caps lead on Tuesday.
There is no 'tech' in tech.
These companies didn't make it any easier on themselves this year.